The most significant early-stage discovery to hit the journals in late 2007 were the dual announcements from two independent research groups that they turned adult human skin cells into cells with properties that are seemingly identical with human embryonic stem (hES) cells.
The most significant early-stage discovery to hit the journals in late 2007 (or at least the most highly publicized) were the dual announcements from two independent research groups that they had managed to turn adult human skin cells into cells with properties that are seemingly identical with human embryonic stem (hES) cells. The teams each inserted four genes (only two of which overlap) into the adult cells to make them revert to the embryonic-like state. Among other things, the achievement may allow US scientists to explore the properties of hES cells—and their potential uses in regenerative medicine—while circumventing the debate on the morality of destroying human embryos to get the cells. Of course, both teams a nd scientific commentators stress that it will take a while to determine how similar the so-called induced pluripotent cells are to true hES cells. For now, however, it may allow US scientists to catch up to foreign counterparts studying hES cells.
Sources:
1. J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, I. I. Slukvin, J. Thomson, "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells," SCIENCEXPRESS, www.sciencexpress.org/, accessed Nov. 20, 2007.
2. K. Takahashi, K. Tanabe, M. Ohnuki, M Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka, "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors," Cell (2007), doi: 10.1016/j.cell.2007.11.019.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.